Please login to the form below

Not currently logged in

Novimmune expands senior management team

Dr Sven Zimmerman and Mylène Fleurant join the Swiss biotech

Novimmune Dr Sven ZimmermanSwiss biotech Novimmune has expanded its senior management team with the appointment of Dr Sven Zimmerman as chief financial officer and Mylène Fleurant as global head of quality.

Dr Zimmerman (pictured) brings over 15 years of scientific and business experience in the biopharma industry, moving to Novimmune from Auris Medical where he served as its chief financial officer.

He is currently a board member of German biotech Epiontis, and has previously served as chief financial officer of PregLem and chairman of Aimago. Prior to this, Dr Zimmerman was a European biotech analyst at UBS Investment Bank.

Fleurant joins Novimmune with 20 years of quality expertise in life sciences, most recently having served as head of quality affairs at Alvotech, an Icelandic biosimilars specialist.

Before joining Alvotech, Fleurant spent 10 years as region head quality assurance, Europe for Novartis and implemented global quality systems at Merck Serono.

Eduard Holdener, chairman and chief executive of Novimmune, said: “We continue to add capabilities to our strong and experienced management team to support our growth strategy.

“With their wealth of professional experience, these two new colleagues will help us to advance Novimmune to the next level as we move closer to the market with our lead programme, NI-0501, which is being developed for the rare disease hemophagocitic lymphohisticocytosis.”

27th September 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge